Seagen Inc.: Seagen Announces Results from Pivotal MOUNTAINE

-Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses- -Results presented in late-breaking oral session at the ESMO World Congress

Related Keywords

United Kingdom , Canada , United States , California , Washington , Switzerland , Spain , Seattle , Barcelona , Comunidad Autonoma De Cataluna , America , American , David Caouette , Roger Dansey , Peggy Pinkston , Johnh Strickler , Duke University School Of Medicine , World Congress On Gastrointestinal , World Congress On Gastrointestinal Cancer , Drug Administration , Lab Abnormalities , Seagen Inc , Nasdaq , Exchange Commission , Approval Program , Corporate Communications , European Union , European Medicines Agency , European Society For Medical Oncology , American Cancer Society Journal , American Cancer Society , European Society , Medical Oncology , World Congress , Gastrointestinal Cancer , Associate Professor , Duke University School , Chief Medical Officer , Confidence Interval , Important Safety Information , New Drug Application , Accelerated Approval , Colorectal Cancer , Metastatic Disease , Response Evaluation Criteria , Solid Tumors , United Kingdom Medicines , Healthcare Products Regulatory Agency , Middle East , Latin America , Important Safety , Prescribing Information , Quarterly Report , Cancer Society Journal , Global Cancer Statistics , Mortality Worldwide , Cancer Society , Key Statistics , Vice President , Investor Relations , Seagen , Nnounces , Results , Rom , Pivotal , Mountaineer , Trial , Emonstrating , Linically , Meaningful , Antitumor , Activity , Tukysa , Tucatinib , Combination , Rastuzumab , Reviously , Reated , Ther2 , Positive ,